HomeCompareALPN vs FCPT

ALPN vs FCPT: Dividend Comparison 2026

ALPN yields 3.08% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FCPT wins by $24.7K in total portfolio value
10 years
ALPN
ALPN
● Live price
3.08%
Share price
$64.97
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.4K
Annual income
$375.35
Full ALPN calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — ALPN vs FCPT

📍 FCPT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALPNFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALPN + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALPN pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALPN
Annual income on $10K today (after 15% tax)
$261.66/yr
After 10yr DRIP, annual income (after tax)
$319.05/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, FCPT beats the other by $4,589.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALPN + FCPT for your $10,000?

ALPN: 50%FCPT: 50%
100% FCPT50/50100% ALPN
Portfolio after 10yr
$36.7K
Annual income
$3,075.31/yr
Blended yield
8.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ALPN right now

ALPN
Analyst Ratings
9
Buy
6
Hold
Consensus: Buy
Price Target
$55.00
-15.3% upside vs current
Range: $44.00 — $65.00
Altman Z
65.0
Piotroski
3/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALPN buys
0
FCPT buys
0
No recent congressional trades found for ALPN or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALPNFCPT
Forward yield3.08%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$24.4K$49.1K
Annual income after 10y$375.35$5,775.28
Total dividends collected$3.4K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$55.00$27.00

Year-by-year: ALPN vs FCPT ($10,000, DRIP)

YearALPN PortfolioALPN Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$11,008$307.83$11,401$700.92$393.00FCPT
2$12,095$316.69$13,064$864.84$969.00FCPT
3$13,267$325.21$15,051$1,072.48$1.8KFCPT
4$14,529$333.38$17,442$1,337.22$2.9KFCPT
5$15,887$341.21$20,340$1,677.08$4.5KFCPT
6$17,348$348.70$23,880$2,116.57$6.5KFCPT
7$18,918$355.85$28,241$2,689.36$9.3KFCPT
8$20,605$362.67$33,660$3,442.07$13.1KFCPT
9$22,417$369.17$40,456$4,439.95$18.0KFCPT
10$24,361$375.35$49,063$5,775.28$24.7KFCPT

ALPN vs FCPT: Complete Analysis 2026

ALPNStock

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Full ALPN Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this ALPN vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALPN vs SCHDALPN vs JEPIALPN vs OALPN vs KOALPN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.